SOURCE: Cryobanks

March 06, 2006 10:00 ET

Cryobanks Begins Road Show in New York

ALTAMONTE SPRINGS, FL -- (MARKET WIRE) -- March 6, 2006 -- Cryobanks International, Inc. (OTC BB: BTEM) announced that it is beginning its roadshow in New York City this week. Initial responses from analysts and portfolio managers have been very positive. Cryobanks will be meeting with leading Wall Street investors, biotechnology funds, high end institutional funds, and well known private equity groups.

Key to the success of Cryobanks International is the emergence of a dynamic and rapidly growing stem cell (cord blood) storage market estimated at over $2 billion worldwide. Currently, only 1% of the addressable market has been penetrated. The Company's primary advantage is its unique business plan which derives revenues from multiple independent sources. Although Cryobanks International receives revenues from family donor storage, like its competition, it has also embarked on a campaign to license its fully operational and FDA-approved storage platform for use in world markets. Already, the Company has closed eight international licensing agreements; one in Athens, Greece and seven in India, and has at least 40 additional licensing agreements in various stages of development.

About Cryobanks:

Cryobanks International, Inc. is a corporation located in Altamonte Springs, Fl., which is to be acquired by BioStem, Inc. (OTC BB: BTEM). The Company is a leader in the collection, processing, and banking of stem cells derived from the umbilical cord immediately after birth. The units of cord blood (CB) are processed and stored by the company for use in unrelated transplants (where the donor is a histocompatible match, but is anonymous and unrelated to the recipient) and for personal storage and use. In recent years, cord blood transplants (CBTs) have become widely recognized as a safe, effective, and in many ways preferable, alternative to bone marrow transplant (BMT). There is tremendous potential need for CBTs in the United States and worldwide. Cryobanks International is well poised to help meet that need, equipped with an inventory of over 8,500 cord blood units. For more information about Cryobanks International call 1-800-869-8608 or visit the website at

Safe Harbor Statement

This press release contains "forward-looking statements" by BioStem, Inc. These statements relate to future events or financial performance and transactions, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements, to be materially different from those contemplated by the forward-looking statements. There can be no assurance that the acquisition described herein will successfully close. We undertake no ongoing obligation, other than that imposed by law, to update these statements. Factors that could affect results, levels of activity, performance or achievements and cause them to materially differ from those contained in the forward-looking statements include the failure to complete the acquisition of Cryobanks, and other factors that can be found in BioStem's filings with the Securities and Exchange Commission, which can be found at

Contact Information